


What is Claimed is:

1. A compound of Formula I,




Formula I

or a pharmaceutically acceptable salt thereof;

wherein,


A is selected from the group consisting of $-NR^1R^2$, $-N=CR^1R^2$,




R^1 , R^2 , R^3 and R^4 are each independently selected from the group consisting of H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{2-6} heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl groups are optionally substituted with a group selected from halogen, OH, NO_2 , NH_2 or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH, NO_2 or NH_2 ;

B is selected from: ethene-1,2-diyl or ;
wherein R^{10} is oxo or OR^{11} ;

wherein R^{11} is H or a heterocycloalkyl, the heterocycloalkyl being optionally substituted with 1-4 substituents selected from OX, C_{1-3} alkyl and $-O-C(O)R^1$, wherein X is H or, when there are at least two neighboring substituent groups that are OX, then the X can be a bond such that the two neighboring oxygen groups form a five-membered acetal ring of the formula:





; wherein R^5 and R^6 are each independently selected from the group consisting of H, C_{1-6} alkyl, and C_{2-7} alkenyl;





D is selected from: $-NR^{12a}R^{12a}$, and OR^{12} , wherein R^{12} is selected from H, C_{1-6} alkyl optionally substituted with 1 to 2


phenyl groups, wherein the phenyl group is optionally substituted with C_{1-6} alkyl or halo;

R^{12a} and R^{12a} are each independently selected from H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{2-6} heterocycloalkyl, aryl, heteroaryl and amino acid, wherein said alkyl, alkenyl, aryl and heteroaryl are optionally substituted with a group selected from halogen, OH, NO_2 , NH_2 or aryl, said aryl being optionally further substituted with one or more groups independently selected from halogen, OH, NO_2 or NH_2 ;






X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹² and X¹³ is each independently selected from H, -C(O)-R⁷ and a bond such that when any of two neighboring X¹, X², X³, X⁴, X⁵, X⁶, X⁷, X⁸, X⁹, X¹² and X¹³ is a bond then the two neighboring oxygen atoms and their attached carbon atoms together form a six-membered acetal ring of the formula:




wherein R⁵, R⁶ and R⁷ are each independently selected from H, C₁₋₆ alkyl, C₂₋₇ alkenyl;

Y¹, Y², Y³, Y⁴, Y⁵, Y⁶, Y⁷, Y⁹, Y¹⁰, Y¹¹, Y¹², Y¹³ and Y¹⁵ are each independently selected from the group consisting of ethene-1,2-diyl,

ethane-1,2-diyl and , wherein said ethene-1,2-diyl and ethane-1,2-diyl groups are optionally substituted with a methyl group;




Z is selected from OH, NHR⁸, and  and when the dotted line is a bond then Z is oxo, or NR⁹;

R⁸ is independently selected from H, C₁₋₆ alkyl, C₂₋₆ alkenyl;


R⁹ is C₁₋₆ alkyl optionally substituted with aryl.

2. The compound of claim 1, wherein Z is oxo, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 2, wherein D is




4. The compound of claim 3, wherein B is




5. The compound of claim 4, wherein A is -NR¹R², or a pharmaceutically acceptable salt thereof.


6. The compound of claim 4, wherein A is -NH-C(=O)-R⁴ or a pharmaceutically acceptable salt thereof.



7. The compound of claim 1, wherein D is




8. A compound of the formula:




Compound 2(a)

9. A compound of the formula II:




Formula II

wherein A^1 is $-NH_2$, $-N=CH-R^{13}$, amino acid or $-NH-R^{14}$, wherein R^{13} is hydrogen or phenyl and R^{14} is selected from the group consisting of isopropyl, 1-(4-nitrophenyl)methyl, cyclohexyl, and wherein said amino acid is attached via its nitrogen atom;




and







wherein R^{15} is selected from the group consisting of methyl, isopropyl, phenyl, 4-nitrophenyl, 1-aminoethyl, 1-amino-1-(4-hydroxyphenyl)methyl, 1-amino-2-(4-hydroxyphenyl)ethyl, 1-amino-2-methylpropyl, 2-pyrrolidinyl and 1-amino-2-hydroxyethyl;


Y^{20} is selected from the group consisting of ethene-1,2-diyl and




Z^1 is selected from the group consisting of:



and




R^{20} is selected from the group consisting of hydrogen and




Y^{30} is ethene-1,2-diyl or ethane-1,2-diyl; and

D^1 is hydroxy, methoxy or




and pharmaceutically acceptable salts thereof.


10. A compound selected from the group consisting of:




Compound 2(b)




Compound 2(c)




Compound 2(d)




Compound 2(e)




Compound 2(f)




Compound 2(g)




Compound 2(h)




Compound 2(i)




Compound 2(j)




Compound 2(k)




Compound 2(l)




Compound 2(m)




Compound 2(n)




Compound 2(o)




Compound 2(p)




Compound 2(q)




Compound 2(r)




Compound 2(s)




Compound 2(t)




Compound 2(u)




Compound 2(v)




Compound 2(w)




Compound 2(x)




Compound 2(y)



Compound 2(z)



Compound 2(aa)



Compound 2(ab)

11. A method for producing the compound of claim 8, comprising the steps of cultivating cells derived from a *Streptomyces aizunensis* strain, incubating said cultured cells aerobically in a growth medium for such time as is required for production of said compound of claim 8, extracting said medium with a solvent and purifying the compound of claim 8 from the crude extract.

12. The method of claim 11 wherein said *Streptomyces aizunensis* strain is NRRL B-11277 or a mutant thereof.

13. The method of claim 12 wherein said mutant is strain [C03]023 (deposit accession number IDAC 070803-1) or [C03U03]023 (deposit accession number IDAC 231203-02).

14. The strain of *Streptomyces aizunensis* identified by deposit accession number IDAC 070803-1.

15. The strain of *Streptomyces aizunensis* identified by deposit accession number number IDAC 231203-02.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 8, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable carrier.

19. A method of treating a fungal infection in a mammal, comprising administering to said mammal suffering from said infection, a therapeutically effective amount of a compound of claim 1.

20. The method of claim 19 wherein said fungal infection is caused by *Candida albicans*.

21. The method of claim 19 wherein said fungal infection is caused by a *Candida sp.*, wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

22. The method of claim 19 wherein said fungal infection is caused by an *Aspergillus sp.*, wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

23. The method of claim 19 wherein said fungal infection is caused by *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor spp.*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; or *S. cerevisiae*.

24. A method of treating a fungal infection in a subject, comprising administering to said subject suffering from said infection, a therapeutically effective amount of a compound of claim 1.

25. The method of claim 24 wherein said fungal infection is caused by a fungus selected from the group consisting of *Candida albicans*, *Candida sp.*, *Aspergillus sp.*, *Fusarium spp.*; *Scedosporium spp.*; *Cryptococcus spp.*; *Mucor spp.*; *Histoplasma spp.*; *Trichosporon spp.*; *Blaspomyces spp.*; and *S. cerevisiae*.

26. The method of claim 24 wherein said *Candida sp.* is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

27. The method of claim 24 wherein said *Aspergillus sp.* is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.